gw pharmaceuticals plc application withdrawn for cannabis based drug gw pharmaceuticals plc withdrew a regulatory application for its key development hope cannabis based pain reliever sativex after united kingdom regulators asked for further data gw shares were down or pence at pence in a broadly higher london market the shares hit a high of pence in but have traded near pence for the past few months the u k based company said it plans to resubmit sativex a treatment for multiple sclerosis spasticity next year and there are "no fundamental concerns" about the drug 
